Voloridge Investment Management
IMVT icon

Voloridge Investment Management’s Immunovant IMVT Stock Holding History

Voloridge Investment Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-31,950
Closed -$515K – 1243
2025
Q3 		$515K Buy
+31,950
New +$517K ﹤0.01% 1097
2023
Q3 		– Sell
-236,543
Closed -$4.49M – 1488
2023
Q2 		$4.49M Sell
236,543
-150,774
-39% -$2.81M 0.02% 709
2023
Q1 		$6.01M Buy
387,317
+181,483
+88% +$3.15M 0.03% 621
2022
Q4 		$3.65M Buy
+205,834
New +$2.59M 0.02% 766
2022
Q1 		– Sell
-180,395
Closed -$1.54M – 1534
2021
Q4 		$1.54M Sell
180,395
-185,398
-51% -$1.53M 0.01% 1150
2021
Q3 		$3.18M Sell
365,793
-2,936
-0.8% -$26.5K 0.02% 866
2021
Q2 		$3.9M Sell
368,729
-61,286
-14% -$856K 0.03% 732
2021
Q1 		$6.9M Buy
+430,015
New +$11.3M 0.05% 431

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Voloridge Investment Management's IMVT Position: Q4 2025 in Review

Voloridge Investment Management sold out of Immunovant (IMVT) in Q4 2025, closing a stake of 31,950 shares — an estimated $515K sold.

Voloridge Investment Management first reported a position in IMVT in Q1 2021 and held it in 8 quarters. The position peaked at $6.9M in Q1 2021. 197 funds tracked by Wall St. Rank hold IMVT as of Q4 2025.

  • Voloridge Investment Management reported no remaining Immunovant position as of Q4 2025 after selling out during the quarter.
  • Voloridge Investment Management sold 31,950 Immunovant shares in Q4 2025, an estimated $515K.
  • Voloridge Investment Management first reported a position in Immunovant in Q1 2021 and held it in 8 quarters.
  • Voloridge Investment Management's Immunovant position peaked at $6.9M in Q1 2021.
  • 197 funds tracked by Wall St. Rank held Immunovant as of Q4 2025.

Based on Voloridge Investment Management's 13F filing for Q4 2025, filed 17 Feb 2026.